Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

doi:10.1371/journal.pone.0005254

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

PloS one - 1 Jan 2009

Spring Michele D, Cummings James F, Ockenhouse Christian F, Dutta Sheetij, Reidler Randall, Angov Evelina, Bergmann-Leitner Elke, Stewart V Ann, Bittner Stacey, Juompan Laure, Kortepeter Mark G, Nielsen Robin, Krzych Urszula, Tierney Ev, Ware Lisa A, Dowler Megan, Hermsen Cornelus C, Sauerwein Robert W, de Vlas Sake J, Ofori-Anyinam Opokua, Lanar David E, Williams Jack L, Kester Kent E, Tucker Kathryn, Shi Meng, Malkin Elissa, Long Carole, Diggs Carter L, Soisson Lorraine, Dubois Marie-Claude, Ballou W Ripley, Cohen Joe, Heppner D Gray

Abstract excerpt

BACKGROUND: This Phase 1/2a study evaluated the safety, immunogenicity, and efficacy of an experimental malaria vaccine comprised of the recombinant Plasmodium falciparum protein apical membrane antigen-1 (AMA-1) representing the 3D7 allele formulated with either the AS01B or AS02A Adjuvant Systems. METHODOLOGY/PRINCIPAL FINDINGS: After a preliminary safety evaluation of low dose AMA-1/AS01B (10 microg/0.5 mL) in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Protozoan

Share to Double-Blind Method

Share to Drug Combinations

Share to Lipid A

Share to Malaria, Falciparum

Share to Malaria Vaccines

Share to Saponins

Source

Open in PubMed Open full text

Identifiers

PMID: 19390585
DOI: 10.1371/journal.pone.0005254
PMCID: PMC2669163

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.PMID 19390585Read ↗

Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults.Semantic proximity Read ↗

Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians.Semantic proximity Read ↗

Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum MalariaSemantic proximity Read ↗

Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.Semantic proximity Read ↗

Apical membrane antigen 1: a malaria vaccine candidate in reviewSemantic proximity Read ↗

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.Semantic proximity Read ↗

Recombinant Viral-Vectored Vaccines Expressing Plasmodium chabaudi AS Apical Membrane Antigen 1: Mechanisms of Vaccine-Induced Blood-Stage ProtectionSemantic proximity Read ↗

Vaccination of Monkeys with RecombinantPlasmodium falciparumApical Membrane Antigen 1 Confers Protection against Blood-Stage MalariaSemantic proximity Read ↗

Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1.Semantic proximity Read ↗

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adultsSemantic proximity Read ↗

Use of immunodampening to overcome diversity in the malarial vaccine candidate apical membrane antigen 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.